Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.
Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy
Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders.
After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of
Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodege
Patients in England and Wales with active lupus nephritis will soon be able to access treatment with Otsuka Pharma’s Lupkynis following a recommendation by the health tech
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.